Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 301–400 of 1,002
The neuronal endosomal-lysosomal system in Alzheimer's disease
Nixon, R. A., Mathews, P. M., & Cataldo, A. M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3114 · Cited by 122
A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels
Lee, M., Guo, J.-P., Kennedy, K., McGeer, E. G., & McGeer, P. L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160748 · Cited by 112
Self-citationPetit, D., Fernández, S. G., Zoltowska, K. M., Enzlein, T., Ryan, N. S., O’Connor, A., Szaruga, M., Hill, E., Vandenberghe, R., Fox, N. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01518-6 · Cited by 120
Alzheimer's Disease, β-Amyloid Protein and Zinc
Huang, X., Cuajungco, M. P., Atwood, C., Moir, R. D., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Nutrition · doi:10.1093/jn/130.5.1488s · Cited by 125
An, S. S., Cai, Y., & Kim, S. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s85808 · Cited by 100
“32,33 PSEN2 mutations are associated with both EOAD and LOAD.”
InfluentialSelf-citationCharacteristics of thein VitroVasoactivity of β-Amyloid Peptides
Crawford, F., Suo, Z., Fang, C., & Mullan, M. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6743 · Cited by 112
Walter, J., Schindzielorz, A., Grünberg, J., & Haass, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1391 · Cited by 111
Yang, X., Yang, Y., Li, G., Wang, J., & Yang, E. S. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9033-7 · Cited by 111
“PS-1 mutation causes a selective increase in Aβ42 relative to Aβ40 both in cultured cells and brains of transgenic mice (Borchelt et al. 1996; Duff et al. 1996; Citron et al. 1997).”
BackgroundMinogue, A. M., Jones, R. S., Kelly, R. J., McDonald, C., Connor, T. J., & Lynch, M. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.026 · Cited by 119
Nyabi, O., Bentahir, M., Horré, K., Herreman, A., Gottardi-Littell, N., Van Broeckhoven, C., Merchiers, P., Spittaels, K., Annaert, W., & De Strooper, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306957200 · Cited by 110
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelova, P., Ruzicka, J., Urdzikova, L., & Sykova, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 102
“Mutation of the APP gene facilitates Aβ production whilst that of PSEN 1 and PSEN2 increases the production of Aβ42 via γ-secretase [13,14].”
BackgroundCrews, L., Rockenstein, E., & Masliah, E. (2010) · Brain Structure and Function · doi:10.1007/s00429-009-0232-6 · Cited by 106
“Consistent with this, in FAD and Down syndrome, production of high levels of Ab1–42 results in early plaque formation (Citron et al. 1997).”
BackgroundIncreased fragmentation of sleep–wake cycles in the 5XFAD mouse model of Alzheimer’s disease
Sethi, M., Joshi, S., Webb, R. L., Beckett, T. L., Donohue, K. D., Murphy, M. P., O’Hara, B. F., & Duncan, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.035 · Cited by 110
“Each of these PS1 and APP mutations increase Aβ42 production but when present together act additively to bring about an excessive Aβ42 burden and hence early onset and aggressive AD pathology (Citron et al., 1997, Eckman et al., 1997, Citron et al., 1998, Oakley et al., 2006).”
BackgroundPharmacogenomics in Alzheimer's Disease
Cacabelos, R. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-205-2_10 · Cited by 109
Deng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108
“…processing of APP, giving rise to increased production of Ab, or a 42 amino acid form of Ab with a high propensity for plaque formation, implying a role for altered APP processing in the pathogenesis of FAD (Goate et al., 1991; Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996).”
BackgroundDewachter, I., Van Dorpe, J., Smeijers, L., Gilis, M., Kuipéri, C., Laenen, I., Caluwaerts, N., Moechars, D., Checler, F., Vanderstichele, H., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06452.2000 · Cited by 105
Genes, models and Alzheimer's disease
Chapman, P. F., Falinska, A. M., Knevett, S. G., & Ramsay, M. F. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02285-5 · Cited by 118
The cellular model for Alzheimer's disease research: PC12 cells
Xie, D., Deng, T., Zhai, Z., Sun, T., & Xu, Y. D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1016559 · Cited by 118
Athan, E. S. (2001) · JAMA · doi:10.1001/jama.286.18.2257 · Cited by 106
“HEK293 cells were stably transfected with APPSwedish and either empty vector in the pcDNA3 vector (mock transfected), wild type PS1 (negative control), Leu392Val mutant PS1 (positive control), or Gly206Ala mutant presenilin 1 plasmids as previously described.(30) For each double transfection, at least 3 independent st…”
MethodWalter, J., Grünberg, J., Capell, A., Pesold, B., Schindzielorz, A., Citron, M., Mendla, K. D., George‐Hyslop, P. S., Multhaup, G., Selkoe, D. J., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5349 · Cited by 131
Self-citationTomita, T., Takikawa, R., Koyama, A., Morohashi, Y., Takasugi, N., Saido, T. C., Maruyama, K., & Iwatsubo, T. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10627.1999 · Cited by 106
“Accumulating data suggest that PS mutations cause AD by promoting the secretion of Ab42 (Borchelt et al., 1996; Duff et al., 1996; Citron et al., 1997; Tomita et al., 1997), although the mechanism whereby mutant (mt) PS leads to the increased production of Ab42 remains unknown.”
BackgroundEvin, G. M., Sernee, M. F., & Masters, C. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00002 · Cited by 119
Chen, F., Gu, Y., Hasegawa, H., Ruan, X., Arawaka, S., Fraser, P., Westaway, D., Mount, H., & St George-Hyslop, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205093200 · Cited by 106
Self-citationLevesque, G., Yu, G., Nishimura, M., Zhang, D. M., Levesque, L., Yu, H., Xu, D., Liang, Y., Rogaeva, E., Ikeda, M., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720999.x · Cited by 107
“…PS2 alter the proteolytic cleavage ofbAPP such that there is a relative increase in the production of longer b-amyloid peptide (Ab) derivatives, i.e., an increase in the ratio of Ab42/Ab40 (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
Self-citationAβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105
“Lastly, several presenilin mutations linked to familial forms of AD are known to increase production of Ab42 cleavage products [14], further implicating this Ab peptide in pathogenesis.”
BackgroundCalpain Activity Regulates the Cell Surface Distribution of Amyloid Precursor Protein
Mathews, P. M., Jiang, Y., Schmidt, S. D., Grbovic, O. M., Mercken, M., & Nixon, R. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205208200 · Cited by 104
Protein Homeostasis, Aging and Alzheimer’s Disease
Morawe, T., Hiebel, C., Kern, A., & Behl, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8246-0 · Cited by 107
“PS1 Increases production of Aβ42, essential for lysosomal proteolysis and autophagy by enabling the acidification of lysosomes required for protease activation [163, 165]”
BackgroundLi, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 119
“[105-108] or ratio of Ab1-42/Ab1-40 [109,110].”
Animal models of dementia and cognitive dysfunction
Neha, N., Sodhi, R. K., Jaggi, A. S., & Singh, N. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.05.017 · Cited by 110
Kurt, M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00084-6 · Cited by 105
Wu, H., Chen, S., Al-Baadani, A., Xu, J., Wu, Q., Pan, K., Zhang, J., & Hong, Y. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8933-0 · Cited by 106
“Missense mutations in the amyloid precursor protein (APP) and presenilin genes can lead to an increase in the production of the amyloid-beta (Aβ) peptide, which can predispose to the development of AD-type brain pathology [65–69].”
BackgroundGenetics of Alzheimer’s Disease
Ridge, P. G., Ebbert, M. T. W., & Kauwe, J. S. K. (2013) · BioMed Research International · doi:10.1155/2013/254954 · Cited by 92
“Here we review the known genetics of early- and late-onset Alzheimer’s disease.”
BackgroundPresenilin structure, function and role in Alzheimer disease
Fraser, P. E., Yang, D.-S., Yu, G., Lévesque, L., Nishimura, M., Arawaka, S., Serpell, L. C., Rogaeva, E. A., & George‐Hyslop, P. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00028-4 · Cited by 118
Self-citationKim, S., Leem, J. Y., Lah, J. J., Slunt, H. H., Levey, A. I., Thinakaran, G., & Sisodia, S. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108245200 · Cited by 107
Self-citationTargeting Synaptic Dysfunction in Alzheimer’s Disease Therapy
Nisticò, R., Pignatelli, M., Piccinin, S., Mercuri, N. B., & Collingridge, G. L. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8324-3 · Cited by 105
Biomarker-based dissection of neurodegenerative diseases
Olsson, B., Zetterberg, H., Hampel, H. J., & Blennow, K. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.006 · Cited by 108
“, 1996) and also when bred with human wild-type APP transgenic mice (Citron et al., 1997).”
BackgroundWinkler, E., Kamp, F., Scheuring, J., Ebke, A., Fukumori, A., & Steiner, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.356659 · Cited by 101
Lamb, B. T., Bardel, K. A., Kulnane, L. S., Anderson, J. J., Holtz, G., Wagner, S. L., Sisodia, S. S., & Hoeger, E. J. (1999) · Nature Neuroscience · doi:10.1038/11154 · Cited by 102
Genetic Factors in the Genesis of Alzheimer's Disease
ST GEORGE‐HYSLOP, P. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05552.x · Cited by 101
Additive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein
Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, W., Levesque, G., St. George Hyslop, P., Younkin, S. G., & Selkoe, D. J. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0183 · Cited by 101
“Furthermore, a mutated PS1 gene was shown to be sufficient to cause increased Ab42 production in the brains of PS1 mutant transgenic mice (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996).”
BackgroundSelf-citationIncreased Aβ42(43) from cell lines expressing presenilin 1 mutations
Mehta, N. D., Refolo, L. M., Eckman, C., Sanders, S., Yager, D., Perez‐Tur, J., Younkin, S., Duff, K., Hardy, J., & Hutton, M. (1998) · Annals of Neurology · doi:10.1002/ana.410430217 · Cited by 101
Transgenic mouse models of Alzheimer’s disease
Janus, C., Chishti, M. A., & Westaway, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00033-8 · Cited by 101
Self-citationAn Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque Depositions
Lee, J.-E., & Han, P.-L. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.2.84 · Cited by 98
“(Tg-PS1 M146L/or M146V and Tg-pNSE-hPS2) carrying FAD mutant forms of PS1 and PS2 (M146L or M146V), respectively, under control of the PDGFβ and NSE promoter show enhanced levels of Aβ42, supporting the hypothesis that the presenilin mutations cause AD pathogenesis through a gain of deleterious function [9, 10, 37].”
BackgroundEckert, A., Steiner, B., Marques, C., Leutz, S., Romig, H., Haass, C., & Müller, W. E. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1064 · Cited by 100
“…and Ab production, which have been sorted out in PC12 cells and other nonneuronal cell lines, such as K293 cells (Haass et al., 1995), are consistent with findings in neuronal cells, human and mouse brain tissue, cerebrospinal fluid, and plasma from AD patients (Citron et al., 1994, 1997).”
ResultModulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 105
“If some mutations occur in the substrate (APP) or in the γ-secretase regulator proteins (prenisilin-1 and prenisilin-2) it may cause an alteration of APP processing, increasing the levels of Aβ1–42 or Aβ1–43 peptides formed [60,61].”
BackgroundWilliams, T. L., Johnson, B. R. G., Urbanc, B., Jenkins, A. T. A., Connell, S. D., & Serpell, L. C. (2011) · Biochemical Journal · doi:10.1042/bj20110750 · Cited by 100
Behavior of neural stem cells in the Alzheimer brain
Waldau, B., & Shetty, A. K. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8053-y · Cited by 98
Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation
Yan, Y., & Wang, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.04.014 · Cited by 99
Intranasal therapeutic strategies for management of Alzheimer’s disease
Sood, S., Jain, K., & Gowthamarajan, K. (2014) · Journal of Drug Targeting · doi:10.3109/1061186x.2013.876644 · Cited by 95
Ertekin-Taner, N., Allen, M., Fadale, D., Scanlin, L., Younkin, L., Petersen, R. C., Graff-Radford, N., & Younkin, S. G. (2004) · Human Mutation · doi:10.1002/humu.20016 · Cited by 97
“…way, their identification should be facilitated by the wellestablished methods for evaluating the effect of mutations on Ab developed in our laboratory [Cai et al., 1993; Suzuki et al., 1994; Duff et al., 1996; Scheuner et al., 1998] and others [Citron et al., 1992, 1997; Borchelt et al., 1996].”
BackgroundPresenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport
Dumanchin, C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1263 · Cited by 99
“Similar increases have be observed in transfected cells lines and transgenic animals express human mutant PSs (28,29).”
BackgroundSeppälä, T. T., Herukka, S., Hänninen, T., Tervo, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 111
Guan, P.-P., Cao, L.-L., & Wang, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115900 · Cited by 93
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 105
Yiu, A. P., Rashid, A. J., & Josselyn, S. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.107 · Cited by 105
Presenilins and Alzheimer's disease
Kim, T.-W., & Tanzi, R. E. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80089-x · Cited by 97
“All of the mutant, but none of the wild-type mice, show an increase in the production of As42 in brain ( 42 , 45).”
BackgroundWengenack, T. M., Whelan, S. L., Curran, G. L., Duff, K., & Poduslo, J. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00388-2 · Cited by 97
Hammer, N. D., Wang, X., McGuffie, B. A., & Chapman, M. R. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13406 · Cited by 91
Translational research in central nervous system drug discovery
Hurko, O., & Ryan, J. L. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.671 · Cited by 106
“Certain features of the human disease are mimicked more closely than others.(4,5) The strong association of apolipoprotein E with propensity to sporadic Alzheimer disease has not influenced drug discovery as strongly despite the availability of animal models.”
BackgroundThe Solved and Unsolved Mysteries of the Genetics of Early-Onset Alzheimer 's Disease
Rogaeva, E. A. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:1:01 · Cited by 113
“…that changes in APP processing are central to AD pathology won further support after the discovery that mutations in the PSs interfere with the cleavage of APP, which causes the overproduction of the most destructive, highly amyloidogenic A 42 peptide (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundRemoving Protein Aggregates: The Role of Proteolysis in Neurodegeneration
A.T. Nijholt, D., De Kimpe, L., L. Elfrink, H., J.M. Hoozemans, J., & Scheper, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843236 · Cited by 93
Cellular Mechanisms for the Biogenesis and Transport of Synaptic and Dense-Core Vesicles
Gondré‐Lewis, M. C., Park, J. J., & Loh, Y. P. (2012) · International review of cytology · doi:10.1016/b978-0-12-394310-1.00002-3 · Cited by 100
Steiner, H., Romig, H., Pesold, B., Philipp, U., Baader, M., Citron, M., Loetscher, H., Jacobsen, H., & Haass, C. (1999) · Biochemistry · doi:10.1021/bi9914210 · Cited by 94
Self-citationDe Jonghe, C., MarcCruts, Rogaeva, E. A., Tysoe, C., Singleton, A., Vanderstichele, H., Meschino, W., Dermaut, B., Vanderhoeven, I., Backhovens, H., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1529 · Cited by 93
Proteostasis and lysosomal repair deficits in transdifferentiated neurons of Alzheimer’s disease
Chou, C.-C., Vest, R., Prado, M. A., Wilson-Grady, J., Paulo, J. A., Shibuya, Y., Moran-Losada, P., Lee, T.-T., Luo, J., Gygi, S. P., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01623-y · Cited by 94
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice
Schüssel, K., Frey, C., Jourdan, C., Keil, U., Weber, C. C., Müller-Spahn, F., Müller, W. E., & Eckert, A. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.041 · Cited by 99
Szczepanik, A. M., Rampe, D., & Ringheim, G. E. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00240.x · Cited by 87
Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations
Lleó, A., Berezovska, O., Growdon, J. H., & Hyman, B. T. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200403000-00006 · Cited by 104
Amyloid-β-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins
Bate, C., & Williams, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248724 · Cited by 89
Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime
McBrayer, M., & Nixon, R. A. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130201 · Cited by 89
AßT Amyloidogenesis: Unique, or Variation on a Systemic Theme
Kisilevsky, R., Fraser, P. E., & Benson, M. D. (1997) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239709082674 · Cited by 103
Self-citationTomita, T., Watabiki, T., Takikawa, R., Morohashi, Y., Takasugi, N., Kopan, R., De Strooper, B., & Iwatsubo, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011152200 · Cited by 91
Brain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits
Nakagawa, Y., Reed, L., Nakamura, M., McIntosh, T. K., Smith, D. H., Saatman, K. E., Raghupathi, R., Clemens, J., Saido, T. C., Lee, V. M.-Y., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7375 · Cited by 91
Hu, L., Wong, T. P., Côté, S. L., Bell, K. F. S., & Cuello, A. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00394-4 · Cited by 90
Pin1 in Alzheimer's disease: Multiple substrates, one regulatory mechanism?
Balaštík, M., Lim, J., Pastorino, L., & Lu, K. P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.01.006 · Cited by 100
Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140327 · Cited by 89
“They usually shift the A generation to the longer A 42 isoform as demonstrated in cellular and transgenic models (Citron et al., 1997) as well as in AD patients (Scheuner et al.”
BackgroundAn overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 98
“PSEN1 missense mutations are responsible for 18%-50% of autosomal dominant cases of EOFAD (Citron, et al., 1997).”
InfluentialKurt, M. A., Davies, D. C., Kidd, M., Duff, K., Rolph, S. C., Jennings, K. H., & Howlett, D. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7717 · Cited by 76
Dietary fats, cerebrovasculature integrity and Alzheimer’s disease risk
Takechi, R., Galloway, S., Pallebage‐Gamarallage, M. M., Lam, V., & Mamo, J. C. L. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.10.004 · Cited by 94
Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility
Theuns, J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.16.2383 · Cited by 87
Mutant Presenilin 2 Transgenic Mice
Sawamura, N., Morishima-Kawashima, M., Waki, H., Kobayashi, K., Kuramochi, T., Frosch, M. P., Ding, K., Ito, M., Kim, T.-W., Tanzi, R. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004308200 · Cited by 87
Steiner, H., Revesz, T., Neumann, M., Romig, H., Grim, M. G., Pesold, B., Kretzschmar, H. A., Hardy, J., Holton, J. L., Baumeister, R., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007183200 · Cited by 85
Rojas, S., Herance, J. R., Gispert, J. D., Abad, S., Llongarriu, È. T., Jiménez, X., Pareto, D., Perpiñá, U., Sarroca, S., Rodríguez, E., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.027 · Cited by 90
The genetics of late-onset Alzheimerʼs disease
Myers, A. J., & Goate, A. M. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00002 · Cited by 88
Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes
Janus, C., D’Amelio, S., Amitay, O. A., Chishti, M. A., Strome, R., Fraser, P., Carlson, G. A., Roder, J., George‐Hyslop, P. S., & Westaway, D. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00107-x · Cited by 95
Self-citationBrody, A. H., & Strittmatter, S. M. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 86
“Experimental validation of the amyloid hypothesis derives from the repeated demonstration that transgenic mice overexpressing human mutant APP with or without mutated forms of presenilin (corresponding to mutations seen in familial AD) develop both senile plaques and age-dependent AD-like phenotypes including synapse…”
BackgroundDissociated phenotypes in presenilin transgenic mice define functionally distinct γ-secretases
Mastrangelo, P., Mathews, P. M., Chishti, M. A., Schmidt, S. D., Gu, Y., Yang, J., Mazzella, M. J., Coomaraswamy, J., Horne, P., Strome, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500940102 · Cited by 93
Self-citationXhima, K., Nabbouh, F., Hynynen, K., Aubert, I., & Tandon, A. (2018) · Movement Disorders · doi:10.1002/mds.101 · Cited by 89
Tang, B. L. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.1.7254 · Cited by 83
Role of Synucleins in Alzheimer’s Disease
Crews, L., Tsigelny, I., Hashimoto, M., & Masliah, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9073-6 · Cited by 84
“Consistent with this, in FAD and Down syndrome, production of high levels of Ab1–42 results in early plaque formation (Citron et al. 1997).”
BackgroundMollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz-Schaeffer, W. J., Ciesielczyk, B., Neumann, M., Steinacker, P., Kretzschmar, H. A., Poser, S., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083178 · Cited by 83
γ-Secretase as a Target for Alzheimer’s Disease
Wolfe, M. S. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00004-0 · Cited by 96
Separation of presenilin function in amyloid β-peptide generation and endoproteolysis of Notch
Kulic, L., Walter, J., Multhaup, G., Teplow, D. B., Baumeister, R., Romig, H., Capell, A., Steiner, H., & Haass, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100049897 · Cited by 85
(2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00006-0 · Cited by 84
Endogenous Presenilin-1 Targets to Endocytic Rather Than Biosynthetic Compartments
Lah, J. J., & Levey, A. I. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0861 · Cited by 84
Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity
Niidome, T., Takahashi, K., Goto, Y., Goh, S., Tanaka, N., Kamei, K., Ichida, M., Hara, S., Akaike, A., Kihara, T., et al. (2007) · NeuroReport · doi:10.1097/wnr.0b013e3280dce5af · Cited by 84
“Constitutive overexpression of familial Alzheimer’s disease-linked mutant genes enhances the production of Ab in vitro and in vivo [5,6].”
BackgroundMurine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 90
JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1
Tamagno, E., Guglielmotto, M., Giliberto, L., Vitali, A., Borghi, R., Autelli, R., Danni, O., & Tabaton, M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.015 · Cited by 88
Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease
Wu, Z., Ciallella, J. R., Flood, D. G., O’Kane, T. M., Bozyczko‐Coyne, D., & Savage, M. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.010 · Cited by 96
γ-Secretase Catalyzes Sequential Cleavages of the AβPP Transmembrane Domain
Xu, X. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0957 · Cited by 84
“This notion was strongly supported by the finding that FAD-linked mutations in both PS1 and PS2 increase the production of Aβ42 in transfected cells and transgenic mice [47–50].”
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.